NasdaqCM - Delayed Quote USD

Nektar Therapeutics (NKTR)

37.83 +0.57 (+1.52%)

At close: 4:00:00 PM EST

37.83 0.00 (0.00%)

After hours: 5:41:52 PM EST

Trade NKTR on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for NKTR

Previous Close 37.26
Open 37.27
Bid 32.75 x 100
Ask 37.80 x 100
Day's Range 36.62 - 38.30
52 Week Range 33.40 - 109.00
Volume 608,168
Avg. Volume 1,096,751
Market Cap (intraday) 1.291B
Beta (5Y Monthly) 1.42
PE Ratio (TTM) --
EPS (TTM) -18.96
Earnings Date Nov 12, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 133.08
Zacks Rating Bullish

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

www.nektar.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NKTR

10.54%

S&P 500 (^GSPC)

10.29%

1-Year Return

NKTR

32.42%

S&P 500 (^GSPC)

12.20%

3-Year Return

NKTR

425.35%

S&P 500 (^GSPC)

73.67%

5-Year Return

NKTR

81.75%

S&P 500 (^GSPC)

61.14%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue 10.13M

Earnings -40.62M

Profit Margin -400.97%

FY25

FY26

-40M

-20M

20M

-400.0%

-350.0%

-300.0%

-250.0%

-200.0%

Analyst Price Targets

50.00

133.08 Average

37.83 Current

192.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/12/2026

Analyst UBS

Rating Action Initiated

Rating Neutral

Price Action Announces

Price Target 53

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-287.84%
Return on Assets (ttm)

-12.54%
Return on Equity (ttm)

-35.76%
Revenue (ttm)

54.59M
Net Income Avi to Common (ttm)

-157.13M
Diluted EPS (ttm)

-18.96

Balance Sheet and Cash Flow

Total Cash (mrq)

684.34M
Total Debt/Equity (mrq)

15.05%
Levered Free Cash Flow (ttm)

-134.77M

ALKS

NBIX

SGMOQ

INCY

EXEL

U.S. markets closed

Nektar Therapeutics (NKTR)

Trading disclosure

2.37%

-8.12%

-53.81%

-10.54%

-32.42%

-81.75%

-33.86%

Nektar Therapeutics Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch